Voyager Therapeutics Stock Price, News & Analysis (NASDAQ:VYGR)

$13.88 0.93 (7.18 %)
(As of 11/21/2017 10:39 AM ET)
Previous Close$12.95
Today's Range$12.66 - $14.15
52-Week Range$8.10 - $25.99
Volume588,400 shs
Average Volume239,727 shs
Market Capitalization$362.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics logoVoyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:VYGR
  • CUSIP: N/A
  • Web: www.voyagertherapeutics.com
Debt:
  • Current Ratio: 6.12%
  • Quick Ratio: 6.12%
Sales & Book Value:
  • Annual Sales: $14.22 million
  • Price / Sales: 30.70
  • Book Value: $5.09 per share
  • Price / Book: 2.73
Profitability:
  • Trailing EPS: ($2.84)
  • Net Income: $-40,190,000.00
  • Net Margins: -1,195.63%
  • Return on Equity: -65.50%
  • Return on Assets: -44.31%
Misc:
  • Employees: 77
  • Outstanding Shares: 31,450,000
 

Frequently Asked Questions for Voyager Therapeutics (NASDAQ:VYGR)

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Thursday, August, 11th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. The firm had revenue of $3.72 million for the quarter, compared to analysts' expectations of $4.79 million. Voyager Therapeutics had a negative return on equity of 65.50% and a negative net margin of 1,195.63%. View Voyager Therapeutics' Earnings History.

Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?

10 equities research analysts have issued twelve-month price targets for Voyager Therapeutics' shares. Their forecasts range from $12.00 to $35.00. On average, they expect Voyager Therapeutics' share price to reach $26.13 in the next twelve months. View Analyst Ratings for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:

  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (11/8/2017)
  • 2. Chardan Capital analysts commented, "We continue to see more likelihood of underappreciated value elsewhere in the Voyager pipeline. Yesterday, after the market close, Voyager Therapeutics announced Sanofi chose not to exercise its exclusive option to ex-US development and commercialization of AAV-based gene therapy (GT), VY-AADC, in aPD." (10/31/2017)
  • 3. Cowen and Company analysts commented, "Tonight we hosted a dinner with VYGR just after the announcement that SNY did not." (10/31/2017)
  • 4. Instinet analysts commented, "We are initiating on Voyager Therapeutics (VYGR) with a Buy rating and $31 target price. We anticipate updates from the ongoing trial of VY-AADC01 confirming efficacy, safety, and framing durability/duration of effect to drive upside in the share price over the next 12 months. In addition, we believe that data and initiation of a pivotal trial in advanced Parkinson's will attract investor attention, as the direct-to-CNS delivery of an enzyme becomes increasingly viewed as a risk-reduced approach to gene therapy with a rapidly addressable $1.5bn DBS-like market opportunity in advanced PD." (3/1/2017)

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,346,882 shares, an increase of 44.9% from the October 13th total of 929,333 shares. Based on an average daily trading volume, of 413,483 shares, the days-to-cover ratio is currently 3.3 days. Currently, 10.2% of the company's shares are short sold.

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:

  • Mark J. Levin, Independent Chairman of the Board (Age 59)
  • Steven M. Paul M.D., President, Chief Executive Officer, Director (Age 66)
  • Jane V Henderson, Chief Financial Officer, Senior Vice President (Age 50)
  • Matthew P. Ottmer, Chief Operating Officer (Age 46)
  • Robert G. Pietrusko, Senior Vice President - Regulatory Affairs (Age 69)
  • Dinah Sah Ph.D., Chief Scientific Officer (Age 56)
  • Kathleen Hayes, Vice President - Human Resources (Age 53)
  • John J. Connelly, Vice President - Program and Alliance Management (Age 47)
  • Bernard Ravina M.D., Chief Medical Officer (Age 50)
  • Glenn F Pierce M.D., Ph.D., Director (Age 61)

Who owns Voyager Therapeutics stock?

Voyager Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Wells Fargo & Company MN (1.40%), Citadel Advisors LLC (0.93%), Point72 Asset Management L.P. (0.42%), Dimensional Fund Advisors LP (0.34%), Mckinley Capital Management LLC Delaware (0.22%) and Bank of New York Mellon Corp (0.23%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina and Steven M Paul. View Institutional Ownership Trends for Voyager Therapeutics.

Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?

Voyager Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Citadel Advisors LLC, Point72 Asset Management L.P., Mckinley Capital Management LLC Delaware, Raymond James Financial Services Advisors Inc., SG Americas Securities LLC, Iguana Healthcare Management LLC and Birchview Capital LP. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy Voyager Therapeutics stock?

Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of Voyager Therapeutics stock can currently be purchased for approximately $13.88.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $362.46 million and generates $14.22 million in revenue each year. The company earns $-40,190,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Voyager Therapeutics employs 77 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 Sidney St, CAMBRIDGE, MA 02139-4134, United States. The company can be reached via phone at +1-857-2595340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Voyager Therapeutics (NASDAQ:VYGR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $26.13 (88.22% upside)

Consensus Price Target History for Voyager Therapeutics (NASDAQ:VYGR)

Price Target History for Voyager Therapeutics (NASDAQ:VYGR)

Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017WedbushReiterated RatingOutperform$22.00 -> $26.00N/AView Rating Details
11/15/2017Canaccord GenuitySet Price TargetBuy$26.00N/AView Rating Details
10/31/2017Chardan CapitalReiterated RatingHold$17.00N/AView Rating Details
10/31/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
10/30/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$31.00N/AView Rating Details
10/23/2017Stifel NicolausReiterated RatingBuy -> Buy$20.00 -> $31.00N/AView Rating Details
10/12/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$35.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$12.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$31.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00N/AView Rating Details
5/20/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Voyager Therapeutics (NASDAQ:VYGR)

Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Earnings History by Quarter for Voyager Therapeutics (NASDAQ VYGR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.62)($0.73)$3.27 million$1.18 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.65)$3.70 million$1.46 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.46)($0.57)$4.15 million$2.36 millionViewN/AView Earnings Details
8/11/2016Q2($0.34)($0.37)$4.79 million$3.72 millionViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29$5.00 million$4.83 millionViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$5.00 million$4.94 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
2017 EPS Consensus Estimate: ($2.64)
2018 EPS Consensus Estimate: ($2.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.76)($0.76)($0.76)
Q4 20171($0.82)($0.82)($0.82)
Q1 20181($0.76)($0.76)($0.76)
Q2 20181($0.77)($0.77)($0.77)
Q3 20181($0.65)($0.65)($0.65)
Q4 20181($0.67)($0.67)($0.67)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Voyager Therapeutics (NASDAQ VYGR)

Insider Ownership Percentage: 8.00%
Institutional Ownership Percentage: 37.04%
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Insider Trades by Quarter for Voyager Therapeutics (NASDAQ VYGR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Bernard RavinaInsiderSell5,490$13.26$72,797.40View SEC Filing  
10/10/2017Bernard RavinaInsiderSell10,980$20.33$223,223.40View SEC Filing  
9/11/2017Bernard RavinaInsiderSell16,470$12.87$211,968.90View SEC Filing  
9/5/2017Bernard RavinaInsiderSell5,490$10.00$54,900.00View SEC Filing  
7/20/2017Bernard RavinaInsiderSell5,490$10.00$54,900.00View SEC Filing  
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Voyager Therapeutics (NASDAQ VYGR)

Source:
DateHeadline
Voyager Therapeutics, Inc. (VYGR) Receives Average Rating of "Hold" from BrokeragesVoyager Therapeutics, Inc. (VYGR) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 3:48 PM
Voyager Therapeutics (VYGR) Outperform Rating Reiterated at WedbushVoyager Therapeutics' (VYGR) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - November 20 at 7:40 AM
Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D DayVoyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day
finance.yahoo.com - November 18 at 10:11 AM
Canaccord Genuity Analysts Give Voyager Therapeutics, Inc. (VYGR) a $26.00 Price TargetCanaccord Genuity Analysts Give Voyager Therapeutics, Inc. (VYGR) a $26.00 Price Target
www.americanbankingnews.com - November 17 at 12:56 AM
Zacks: Analysts Expect Voyager Therapeutics, Inc. (VYGR) Will Announce Quarterly Sales of $5.05 MillionZacks: Analysts Expect Voyager Therapeutics, Inc. (VYGR) Will Announce Quarterly Sales of $5.05 Million
www.americanbankingnews.com - November 14 at 6:04 AM
Bernard Ravina Sells 5,490 Shares of Voyager Therapeutics, Inc. (VYGR) StockBernard Ravina Sells 5,490 Shares of Voyager Therapeutics, Inc. (VYGR) Stock
www.americanbankingnews.com - November 13 at 6:28 PM
Voyager Therapeutics to Present at Investor Conferences in NovemberVoyager Therapeutics to Present at Investor Conferences in November
feeds.benzinga.com - November 13 at 2:28 PM
Voyager Therapeutics, Inc. (VYGR) Short Interest Up 44.9% in OctoberVoyager Therapeutics, Inc. (VYGR) Short Interest Up 44.9% in October
www.americanbankingnews.com - November 13 at 2:32 AM
Voyager Therapeutics to Host R&D Day on November 16, 2017Voyager Therapeutics to Host R&D Day on November 16, 2017
finance.yahoo.com - November 12 at 6:26 PM
Zacks: Analysts Anticipate Voyager Therapeutics, Inc. (VYGR) to Announce -$0.76 EPSZacks: Analysts Anticipate Voyager Therapeutics, Inc. (VYGR) to Announce -$0.76 EPS
www.americanbankingnews.com - November 12 at 3:36 PM
Voyager Therapeutics Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)Voyager Therapeutics Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 12 at 1:20 PM
Voyager Therapeutics Announces Closing of Public Offering of Common StockVoyager Therapeutics Announces Closing of Public Offering of Common Stock
finance.yahoo.com - November 12 at 1:20 PM
Voyager Therapeutics Announces Closing of Public Offering of Common StockVoyager Therapeutics Announces Closing of Public Offering of Common Stock
finance.yahoo.com - November 12 at 1:20 PM
Voyager Therapeutics Gears Up for Secondary OfferingVoyager Therapeutics Gears Up for Secondary Offering
finance.yahoo.com - November 9 at 9:45 AM
Voyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : November 8, 2017Voyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : November 8, 2017
finance.yahoo.com - November 9 at 9:45 AM
ETFs with exposure to Voyager Therapeutics, Inc. : November 8, 2017ETFs with exposure to Voyager Therapeutics, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 9:44 AM
Voyager Therapeutics, Inc. (VYGR) Rating Lowered to Sell at Zacks Investment ResearchVoyager Therapeutics, Inc. (VYGR) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 8 at 2:54 PM
Voyager Therapeutics Announces Proposed Offering of Common Stock - GlobeNewswire (press release)Voyager Therapeutics Announces Proposed Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 8 at 4:32 AM
Voyager Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)Voyager Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 8 at 4:32 AM
Voyager Therapeutics Announces Pricing of Public Offering of Common StockVoyager Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - November 7 at 11:31 PM
Voyager Therapeutics Announces Proposed Offering of Common StockVoyager Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - November 7 at 1:23 PM
Voyager Therapeutics, Inc. :VYGR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Voyager Therapeutics, Inc. :VYGR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 1:23 PM
Voyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : November 6, 2017Voyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : November 6, 2017
finance.yahoo.com - November 6 at 9:09 AM
Voyager Therapeutics (VYGR) CEO Steve Paul on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaVoyager Therapeutics' (VYGR) CEO Steve Paul on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 5 at 7:21 AM
Edited Transcript of VYGR earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of VYGR earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 9:47 AM
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate HighlightsVoyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - November 2 at 9:04 PM
Voyager Therapeutics reports 3Q lossVoyager Therapeutics reports 3Q loss
finance.yahoo.com - November 2 at 9:04 PM
Q3 2017 Earnings Estimate for Voyager Therapeutics, Inc. (VYGR) Issued By WedbushQ3 2017 Earnings Estimate for Voyager Therapeutics, Inc. (VYGR) Issued By Wedbush
www.americanbankingnews.com - November 2 at 6:46 AM
Voyager Therapeutics (VYGR) Says Sanofi Genzyme Decided Not to Exercise its Rights to VY-AADC ProgramVoyager Therapeutics (VYGR) Says Sanofi Genzyme Decided Not to Exercise its Rights to VY-AADC Program
www.streetinsider.com - November 1 at 10:40 AM
Voyager Therapeutics to Host Third Quarter 2017 Financial Results and Corporate Highlights Conference CallVoyager Therapeutics to Host Third Quarter 2017 Financial Results and Corporate Highlights Conference Call
finance.yahoo.com - November 1 at 10:40 AM
Voyager Therapeutics Announces Update to Parkinson’s Disease ProgramVoyager Therapeutics Announces Update to Parkinson’s Disease Program
finance.yahoo.com - November 1 at 10:40 AM
Who Really Owns Voyager Therapeutics Inc (VYGR)?Who Really Owns Voyager Therapeutics Inc (VYGR)?
finance.yahoo.com - November 1 at 10:40 AM
Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All FrontsBiotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts
finance.yahoo.com - November 1 at 10:40 AM
Cowen and Company Reaffirms Buy Rating for Voyager Therapeutics, Inc. (VYGR)Cowen and Company Reaffirms Buy Rating for Voyager Therapeutics, Inc. (VYGR)
www.americanbankingnews.com - October 31 at 2:48 PM
Voyager Therapeutics, Inc. (VYGR) Given "Hold" Rating at Chardan CapitalVoyager Therapeutics, Inc. (VYGR) Given "Hold" Rating at Chardan Capital
www.americanbankingnews.com - October 31 at 2:41 PM
3 Stocks to Watch on Tuesday: Mondelez International Inc (MDLZ), SBA Communications Corporation (SBAC) and ... - Investorplace.com3 Stocks to Watch on Tuesday: Mondelez International Inc (MDLZ), SBA Communications Corporation (SBAC) and ... - Investorplace.com
investorplace.com - October 31 at 12:00 PM
Voyager Therapeutics (VYGR): Thoughts After Management Dinner - Cowen - StreetInsider.comVoyager Therapeutics (VYGR): Thoughts After Management Dinner - Cowen - StreetInsider.com
www.streetinsider.com - October 31 at 12:00 PM
Voyager Therapeutics (VYGR) Says Sanofi Genzyme Decided Not to Exercise its Rights to VY-AADC Program - StreetInsider.comVoyager Therapeutics (VYGR) Says Sanofi Genzyme Decided Not to Exercise its Rights to VY-AADC Program - StreetInsider.com
www.streetinsider.com - October 31 at 11:59 AM
Bad Luck Bites Biotech AnalystBad Luck Bites Biotech Analyst
finance.yahoo.com - October 31 at 11:59 AM
Voyager Therapeutics, Inc. (VYGR) Receives "Positive" Rating from WedbushVoyager Therapeutics, Inc. (VYGR) Receives "Positive" Rating from Wedbush
www.americanbankingnews.com - October 31 at 9:54 AM
3 Stocks to Watch on Tuesday: Mondelez International Inc (MDLZ), SBA Communications Corporation (SBAC) and Voyager Therapeutics Inc (VYGR)3 Stocks to Watch on Tuesday: Mondelez International Inc (MDLZ), SBA Communications Corporation (SBAC) and Voyager Therapeutics Inc (VYGR)
investorplace.com - October 31 at 8:31 AM
Voyager Therapeutics, Inc. (VYGR) Earns Outperform Rating from Analysts at Robert W. BairdVoyager Therapeutics, Inc. (VYGR) Earns Outperform Rating from Analysts at Robert W. Baird
www.americanbankingnews.com - October 30 at 6:34 PM
Voyager Therapeutics, Inc. (VYGR) Coverage Initiated at Canaccord GenuityVoyager Therapeutics, Inc. (VYGR) Coverage Initiated at Canaccord Genuity
www.americanbankingnews.com - October 27 at 9:38 AM
Voyager Therapeutics, Inc. (VYGR) Given Consensus Recommendation of "Buy" by AnalystsVoyager Therapeutics, Inc. (VYGR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 26 at 5:48 PM
$1.15 Million in Sales Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter$1.15 Million in Sales Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter
www.americanbankingnews.com - October 25 at 3:42 PM
Voyager Therapeutics (VYGR) and Its Competitors Critical SurveyVoyager Therapeutics (VYGR) and Its Competitors Critical Survey
www.americanbankingnews.com - October 25 at 2:28 AM
Zacks: Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Announce Earnings of -$0.72 Per ShareZacks: Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - October 23 at 2:12 PM
Voyager Therapeutics, Inc. (VYGR) Price Target Raised to $31.00 at Stifel NicolausVoyager Therapeutics, Inc. (VYGR) Price Target Raised to $31.00 at Stifel Nicolaus
www.americanbankingnews.com - October 23 at 7:26 AM
Voyager Therapeutics (VYGR) Reports New Data on Recent Results for Phase 1b Trial of VY-AADC01Voyager Therapeutics (VYGR) Reports New Data on Recent Results for Phase 1b Trial of VY-AADC01
www.streetinsider.com - October 18 at 4:16 PM
Voyager Therapeutics (VYGR) Reports New Data on Recent Results for Phase 1b Trial of VY-AADC01 - StreetInsider.comVoyager Therapeutics (VYGR) Reports New Data on Recent Results for Phase 1b Trial of VY-AADC01 - StreetInsider.com
www.streetinsider.com - October 18 at 10:31 AM

Social Media

Financials

Chart

Voyager Therapeutics (NASDAQ VYGR) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.